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Open Access

Intra-thoracic fat volume is associated with
myocardial infarction in patients with metabolic
syndrome
Umjeet S Jolly1, Abraam Soliman2,5, Charles McKenzie2,3,4, Terry Peters2,3,4, John Stirrat2, Immaculate Nevis2,
Matthew Brymer2, Tisha Joy1,2, Maria Drangova2,4 and James A White1,2,3,6*

Abstract
Background: Visceral adiposity is increased in those with Metabolic Syndrome (MetS) and atherosclerotic disease
burden. In this study we evaluate for associations between intra-thoracic fat volume (ITFV) and myocardial infarction
(MI) in patients with MetS.
Methods: Ninety-four patients with MetS, MI or both were identified from a cardiovascular CMR clinical registry.
MetS was defined in accordance to published guidelines; where-as MI was defined as the presence of
subendocardial-based injury on late gadolinium enhancement imaging in a coronary vascular distribution. A
healthy control group was also obtained from the same registry. Patients were selected into the following groups:
MetS+/MI- (N = 32), MetS-/MI + (N = 30), MetS+/MI + (N = 32), MetS-/MI- (N = 16). ITFV quantification was performed
using signal threshold analysis of sequential sagittal CMR datasets (HASTE) and indexed to body mass index.
Results: The mean age of the population was 59.8 ± 12.5 years. MetS+ patients (N=64) demonstrated a significantly
higher indexed ITFV compared to MetS- patients (p = 0.05). Patients in respective MetS-/MI-, MetS+/MI-, MetS-/MI+,
and MetS+/MI + study groups demonstrated a progressive elevation in the indexed ITFV (22.3 ± 10.6, 28.6 ± 12.6,
30.6 ± 12.3, and 35.2 ± 11.4 ml/kg/m2, (p = 0.002)). Among MetS+ patients those with MI showed a significantly
higher indexed ITFV compared to those without MI (p = 0.02).
Conclusions: ITFV is elevated in patients with MetS and incrementally elevated among those with evidence of
prior ischemic myocardial injury. Accordingly, the quantification of ITFV may be a valuable marker of myocardial
infarction risk among patients with MetS and warrants further investigation.
Keywords: Fat distribution, Adiposity, Metabolic syndrome, Myocardial infarction

Background
Visceral adiposity is a recognized phenotypic feature of
Metabolic Syndrome (MetS) and may be a quantifiable
imaging marker of atherosclerotic disease risk [1-3]. The
intra-thoracic fat volume (ITFV) is one such marker shown
to be reproducible by thoracic computed tomography (CT)
imaging, and appears to correlate with other validated
cardiovascular risk prediction models [4,5] as well as serologic markers of vascular inflammation [6]. ITFV has been
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associated with the extent of coronary artery calcification
[7], suggesting association with coronary artery disease
(CAD) burden. This measure has also been shown to be
independently predictive of future cardiovascular events
among a broad referral population receiving cardiac CT
for the evaluation of acute chest pain [8]. However, among
patients with MetS, whether ITFV quantification may
discriminate risk of ischemic myocardial injury remains
unclear.
Within this cohort study we explore associations
between ITFV and the presence of ischemic myocardial
injury (ie: myocardial infarction) among patients meeting
criteria for MetS. ITFV measures were compared to control populations of patients without MetS both with and
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without prior myocardial infarction. A novel, rapid cardiovascular magnetic resonance (CMR) based approach to
the quantification of ITFV was employed and validated.

Methods
Patient population

Ninety-four patients with metabolic syndrome (MetS)
and/or myocardial infarction (MI) undergoing Late Gadolinium Enhancement (LGE) were identified from a clinical
CMR registry at the Cardiovascular MR Clinical Research
(CMCR) program between March 2009 and March 2011.
MetS was defined in accordance with published guidelines
[9] as any three of the following five criteria: body mass
index (BMI) ≥30 kg/m2, serum triglycerides ≥1.7 mmol/L,
high density lipoprotein C (HDL-C) ≤1.0 mmol/L for men
or ≤1.3 mmol/L for women, Hemoglobin A1C ≥6.5%,
systolic blood pressure ≥130 mm Hg or diastolic blood
pressure ≥85 mm Hg. Current pharmacologic therapy
for hyperlipidemia, diabetes, or hypertension was considered equivalent to their respective criteria. The presence of MI was defined as the unequivocal presence of
subendocardial-based (ie: ischemic) enhancement on LGE
CMR, confirmed in two imaging planes. In addition, 16
normal subjects were identified to serve as a control
population for ITFV measurement, each required to
have no history of MetS or overt cardiovascular disease.
Based upon the established inclusion criteria 4 groups
were available for analysis: MetS without MI (MetS+/MI-)
[N = 32], MetS with MI (MetS+/MI+) [N = 32], No MetS
with MI (MetS-/MI+) [N = 30], and No MetS and No MI
(MetS-/MI-) [N = 16].
Patients with a Glomerular Filtration Rate (GFR) of
≤30 ml/min/1.73 m2 were excluded due to FDA recommendation against the administration of gadolinium-based
contrast agents in this population [10]. Patients with standard contraindications to CMR were similarly excluded.
Ethics approval was obtained for this study from the
University of Western Ontario Research Ethics Board.
Cardiovascular MR protocol

CMR was performed using 3 T MRI scanners (TIM Trio
or Verio, Siemens, Erlangen, Germany). Images were obtained using a 32-channel phased-array radiofrequency
coil with ECG-gating. All patients had thoracic imaging
performed in the sagittal orientation inclusive of both
humeral heads using a Half-Fourier Acquisition Singleshot Turbo-spin Echo (HASTE) pulse sequence during
shallow breathing (slice thickness 8 mm, gap 2 mm, matrix
256 x 155, FOV 400–450 x 350-400 mm, TE 50 ms, TR
600 ms, iPAT 2). The typical imaging time required for this
survey was 25–30 seconds (1 image slice per cardiac cycle),
depending upon heart rate (See Figure 1). Cardiac function
was assessed in the short-axis orientation at 10-mm intervals from the atrioventricular annulus to apex and in the

Page 2 of 9

2, 3 and 4-chamber views using a standard SSFP-based
pulse sequence (slice thickness 6-mm, gap 4-mm, TE
1.3 ms, flip angle 10 degrees, matrix 256x205, iPAT 2,
temporal resolution 28-38 ms). Ten to fifteen minutes
following the intravenous administration of Gadolinium
contrast (0.1 to 0.2 mmol/kg, Gadovist®, Bayer, Inc),
LGE imaging was performed using a standard segmented
inversion-recovery gradient echo pulse sequence in imaging planes identical to cine images. Typical imaging
parameters were: slice thickness = 6 mm; gap = 4 mm;
TR = 800 ms; TE = 3.9 ms; flip angle = 20 degrees; matrix
256 x 205; trigger pulse = 2; segments 13–21; iPAT = 2.
The inversion time was optimized to null normal myocardium, as previously described [11].
CMR image analysis: cine and delayed enhancement
imaging

All cine and LGE-CMR datasets were blindly analyzed by
an experienced CMR interpreter as part of a standardized,
core-laboratory protocol. All quantitative analysis was
performed using the same commercially available analysis
software (CMR42, Circle Cardiovascular Inc, Calgary).
The LV end-systolic volume (ESV), LV end-diastolic volumes (EDV) and LV mass were obtained using semiautomated contour tracing of sequential short axis cine
image datasets. LGE imaging was visually scored for
the presence of any abnormal enhancement and its
transmural distribution. Only patients with unequivocal
subendocardial contrast enhancement in two or more
contiguous / orthogonal image slices not associated with
artifact were labeled as having MI. Signal quantification
of LGE images was incrementally performed using a
Signal Threshold Versus Reference Myocardium (STRM)
technique to measure infarct mass, as previously described
[12]. This technique was performed by manual tracing of
the endocardial and epicardial contours with the tracing
of the largest contiguous region of normal reference myocardium. Total scar volume was determined using a signal
threshold of ≥5SD above the mean signal of normal reference myocardium. Total infarct mass was expressed as a
percentage of the total LV mass.
CMR image analysis: thoracic fat quantification

To determine a standardized signal threshold for fat
quantification on HASTE imaging we performed a visual
calibration study, referencing CT-based fat segmentation
performed using previously validated techniques [7,13,14].
This was performed in 10 study patients who had also
received cardiac CT imaging within one month of their
CMR study. In these patients their CMR and CT datasets
were simultaneously displayed, the latter re-formatted
using a 3D multi-planar reconstruction (MPR) to provide anatomically matched slice orientations of three
randomly selected MR imaging planes (total of 30 slices

Jolly et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:77
http://jcmr-online.com/content/15/1/77

Page 3 of 9

Figure 1 Example images using free-breathing magnetic resonance imaging in sagittal plane employing the HASTE pulse sequence.
Adipose tissue demonstrates high signal relative to all other tissues.

evaluated) (OsirX, Version 4.0). Manual contour tracing
of the intra-thoracic borders was performed for all selected images, the anatomic limits defined as the level
of the clavicle superiorly, the diaphragm inferiorly, the
sternum anteriorly, and the vertebral bodies / ribs,
posteriorly. An example of this is shown in Figure 2. A
validated signal threshold fat signal range (−190 to −30
Hounsfield units [7,13,14]) was applied to highlight adipose tissue on the CT image. Five randomly selected
regions of paravertebral muscle were selected on the
corresponding CMR dataset to serve as a signal reference,
the mean signal and SD of these regions determined using

a 5–10 mm region of interest. This was followed by manual adjustment of the signal threshold on the CMR image,
described by SD above this mean value, until a visual
match of intra-thoracic fat segmentation was obtained between the two images. Using this process a signal threshold of ≥10 SD above the mean signal of paravertebral
muscle was consistently found to be most effective in identifying intra-thoracic adipose tissue on HASTE images
compared to CT-based segmentation.
CMR-based quantification of the ITFV was blindly performed on sequential sagittal HASTE images using manual
contour tracing of the intra-thoracic border, as described

Figure 2 Example of signal threshold based analysis technique from a mid thoracic sagittal HASTE image. Green line = Outer limits
(parietal thoracic border), Red line = Inner limits (cardiac chamber shown), Blue line = reference tissue (paravertebral skeletal muscle).
Yellow = segmented fat signal.
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above, followed by applying the signal threshold of ≥10 SD
above the mean signal of paravertebral muscle. The total
ITFV was derived as the sum of fat signal area from all
slices multiplied by the total slice thickness. ITFV was
indexed to the patients’ body mass index (BMI). Total analysis time for measurement of ITFV from HASTE imaging
ranged from 8 to 14 minutes.
Intra-observer and inter-observer variability of ITFV
quantification was evaluated by the repeated measurement of 10 randomly selected study patients by two

interpreters. This was performed in random order on two
separate occasions.
Statistical analysis

Continuous variables are presented as mean ± SD or
median (range) depending on distribution. Parameters
with normal distribution were tested using independentsample t test (2-tailed distribution) for two group comparison whereas means of more than two groups were
compared using Analysis of Variance (ANOVA). For

Table 1 Baseline clinical characteristics according to patient cohort (Total N = 110)
Characteristic
Age (years)
Female sex (%)
Caucasian (%)

MetS-MI- (n = 16)

MetS + MI- (n = 32)

MetS-MI + (n = 30)

MetS + MI + (n = 32)

42.3 ± 16.9

62.0 ± 10.2

60.1 ± 11.4

58.7 ± 14.8

7 (44%)

7 (23%)

4 (14%)

3 (9%)

10 (62%)

25 (81%)

23 (79%)

26 (79%)

22.9 (21.7 – 24.0)

32.5 (30.3 – 34.8)

26.0 (24.5 – 27.5)

30.4 (28.7 – 32.0)

88.7 ± 25

119.9 ± 9

106.4 ± 14.3

116.0 ± 11

94 ± 18

81 ± 23

78 ± 20

76 ± 21

Hypertension

0 (0%)

24 (77%)

13 (45%)

23 (70%)

Diabetes

0 (0%)

14 (45%)

2 (7%)

14 (42%)

Type I

0

2

0

0

BMI (kg/m2)
Waist circumference (cm)
eGFR (ml/minute)
Comorbidities (%)

0

12

2

14

Hyperlipidemia

Type II

0 (0%)

28 (90%)

16 (55%)

24 (73%)

Smoking

2 (12%)

13 (42%)

11 (38%)

15 (46%)

Prior PCI or CABG

0 (0%)

10 (32%)

12 (41%)

19 (58%)

NA

0.08 (0.06 – 0.09)

0.06 (0.05 – 0.07)

0.07 (0.05 - 0.07)

Blood profile
HgbA1c
Total cholesterol

4.9 (3.8 – 6.1)

3.8 (3.4 – 4.3)

4.2 (3.6 – 4.7)

4.0 (3.5 – 4.5)

Triglyceride

1.2 (0.8 – 1.6)

2.0 (1.6 – 2.5)

1.3 (0.9 – 1.6)

1.9 (1.3 – 2.4)

HDL

1.3 (0.8 – 1.7)

0.9 (0.8 – 1.0)

1.2 (1.0 – 1.3)

0.9 (0.8 – 1.0)

LDL

3.1 (2.2 – 4.1)

2.1 (1.6 – 2.5)

2.5 (1.9 – 3.0)

2.3 (1.8 - 2.7)

Total cholesterol/HDL ratio

4.1 (2.9 – 5.3)

4.3 (3.9 – 4.8)

3.9 (3.1 – 4.7)

4.7 (3.8 – 5.6)

Current medications
Aspirin (ASA)

4 (25%)

15 (46.9%)

21 (70.0%)

22 (68%)

ACE inhibitor

2 (12.5%)

10 (31.3%)

21 (70.0%)

21 (65.7%)

ARB

0 (0%)

9 (28.1%)

3 (10%)

8 (25%)

Beta blocker

5 (31.3%)

26 (81.3%)

24 (80.0%)

25 (78.1%)

Diuretic

1 (6.3%)

11 (34.4%)

7 (23.3%)

17 (53.1%)

Fibrate

0 (0%)

1 (3.1%)

1 (3.3%)

2 (6.3%)

Insulin

0 (0%)

1 (3.1%)

0 (0%)

2 (6.3%)

Oral Hypoglycemic

0 (0%)

11 (34.4%)

2 (6.7%)

8 (25%)

Statin

2 (12.5%)

24 (75%)

16 (53.3%)

19 (59.4%)

Plavix

0 (0%)

4 (12.5%)

6 (20.0%)

7 (21.9%)

Results are presented as a mean with 95% confidence interval for continuous data or number with proportion for categorical data. MetS Metabolic Syndrome,
MI Myocardial Infarction, BMI Body Mass Index, PCI Percutaneous Coronary Intervention, CABG Coronary Artery Bypass Grafting, Hgb Hemoglobin, HDL High
density lipoprotein, LDL Low density lipoprotein, ASA Aspirin, ACE Angiotensin converting enzyme.
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non-normally distributed continuous data (reported as
medians and range), the Mann–Whitney U or Kruskal
Wallis test was used. Categorical data are summarized
as frequencies and percentages between groups using the
chi-square test or the Fisher exact test as appropriate.
Multivariable linear regression analysis was used to
determine significant predictors of total scar volume.
Reproducibility of ITFV analysis was assessed by linear
regression analysis, and the Pearson correlation coefficient (r) is reported for inter- and intra- observer variability of both measures. Bland and Altman analysis was
performed to evaluate for systematic bias.
All statistical tests were two-tailed and p <0.05 was
regarded as significant. S-Plus (version 8.0, Insightful
Software, Seattle, WA) was used to perform the statistical analyses.

Results
Baseline patient characteristics

Baseline clinical characteristics are shown in Table 1.
The mean age of the study population was 59.8 ± 12.5 years
with 78% being male and 71% being Caucasian. Patients
with MetS were more likely to be receiving oral
hypoglycemic therapy, lipid lowering therapy and antihypertensive therapy. Higher triglyceride levels were
seen in those with MetS while LDL values were modest
due to concurrent pharmacologic therapy.
Of the 62 patients demonstrating LGE-CMR evidence
of prior MI 10 (16%) were clinically silent with no history of a clinical event. The mean time interval between
the most recent clinically recognized MI and CMR was
0.9 ± 2.3 years.
Cardiovascular MR findings
Cine and delayed enhancement imaging

The results of cine and LGE-MRI analysis are summarized in Table 2. Significant differences in the LVEDV,
LVEF and LV mass were identified between those with

prior MI (MetS+/MI + and MetS-/MI+) and those without prior MI (p < 0.01 for all comparisons).
The extent of myocardial infarction ranged from large,
multi-territory transmural injury to small, discrete subendocardial injury, as shown in Figure 3. This injury was
seen in a single coronary artery territory in 42 patients
(68%) and ≥2 territories in 20 patients (32%). Using signal
threshold-based quantification of LGE no differences in
total infarct size was identified between those without
MetS versus those with MetS (20.6 ± 14.2% versus
19.8 ± 13.5%, respectively, p = 0.97).

Intra-thoracic fat volume (ITFV) quantification

The results of ITFV quantification are summarized in
Table 2. The indexed ITFV was significantly different among
the four patient cohorts (p = 0.002, ANOVA) (Figure 4).
Incremental elevation in the ITFV was identified for
the following cohorts; MetS+/MI–, MetS-/MI+, and
MetS+/MI+, respectively, each demonstrating statistically significant elevations when compared to control
subjects (p = 0.08, p = 0.02, p = 0.0005, respectively). Among
patients with MetS, the indexed ITFV was significantly
higher among those with LGE-MRI evidence of MI versus those without MI (35.2 ± 11.4 ml/kg/m2 vs 28.6 ±
12.6 ml/kg/m2, p = 0.02).
Multivariable linear regression analysis was performed
among the entire population to explore for independent
associations with total infarct volume. The following variables were entered into this model; indexed ITFV, age,
sex, race, BMI, diabetes and GFR. This revealed indexed
ITFV to be the strongest independent predictor of infarct volume following adjustment for all other variables
(Beta 0.8, p = 0.01). A significant association (ie: co-linearity)
was present between indexed ITFV and both waist circumference and hypertension (p = 0.005), preventing their inclusion in the same model. However, replacement of indexed
ITFV with either variable resulted in a lower strength of

Table 2 Baseline CMR characteristics according to patient cohort (Total N = 110)
Characteristic
LV EDV (indexed to BSA)
LV EF (%)
LV mass (indexed to BSA)

MetS-MI- (n = 16)

MetS + MI- (n = 32)

MetS-MI + (n = 30)

MetS + MI + (n = 32)

78.9 (59.4–98.4)

80.2 (66.8–93.6)

99.8 (87.3–112.3)*

113.0 (98.3–127.6)*

63 (54 – 72)

58 (50 – 66)

40 (33 – 47)*

34 (29 – 40)*

71.2 (56.6-85.9)

74.1 (65.6-82.7)

82.6 (75.2-89.9) *

90.2 (81.8-98.6) *

Injury pattern on LGE CMR

0

0

30 (100%)

32 (100%)

−1 vascular territory

NA

NA

24 (80%)

18 (56.3%)

- ≥ 2 vascular territories
Total scar (% LV Mass)

NA

NA

6 (20%)

14 (43.8%)

2.1 ± 2.1

3.6 ± 7.5

21.1 ± 14.7*

21.0 ± 15.4*

Non-indexed ITFV (ml)

191 ± 125

506 ± 269*

500 ± 293*

668 ± 292*

Indexed ITFV (ml/kg/m2)

22.3 ± 10.6

28.6 ± 12.6*

30.6 ± 12.3*

35.2 ± 11.4*

Results are presented as a mean with 95% confidence interval for continuous data or number with proportion for categorical data. *Indicates p < 0.05 versus
control population. LV Left Ventricle, BSA Body Surface Area, EDV End Diastolic Volume, EF Ejection Fraction, DE Delayed Enhancement, ITFV Intra-thoracic
Fat Volume.
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Figure 3 Examples of myocardial infarctions identified by Late Gadolinium Enhancement imaging in patients with Metabolic Syndrome.
Left: Patient with a large, clinically recognized anteroseptal myocardial infarction. Right: Patient with a small, clinically silent subendocardial infarction in
the posterolateral wall.

association, suggesting indexed ITFV to be more robustly
associated with infarct burden.
Intra and inter-observer variability

Intra-observer reproducibility for ITFV measurements was
excellent with a Pearson correlation coefficient of 0.97,
while the inter-observer data showed a coefficient of
0.76 (Figure 5). Bland and Altman analyses demonstrated
no significant bias for either intra-observer or interobserver testing [1.2 (95% CI −146.3 to 148.7), and
−60.5 (95% CI −386.7 to 265.7), respectively].

Discussion
This study is the first to identify an association between
thoracic visceral adiposity and the occurrence of myocardial

Figure 4 Intra-thoracic Fat Volume (ITFV), indexed to body mass
index, for Control patients and for the 3 disease patient cohorts.
MetS = Metabolic Syndrome. MI = Myocardial Infarction (as determined
by LGE CMR).

infarction. Our results indicate that, among a sampled cohort of patients undergoing CMR imaging, ITFV is both
associated with MetS and is incrementally elevated among
those with objective evidence of myocardial infarction.
An expanding body of evidence supports that MetS
patients experience an alteration in adipose tissue distribution to the visceral surfaces of abdominal [15] and
mediastinal organs [16]. These two visceral fat repositories
are recognized to have common embryologic origins [2]
and share similar metabolic profiles that contribute to increased production of inflammatory cytokines, such as;
interleukin-6, interleukin-8, and TNF-α. [17]. These mediators may exert both a local cytotoxic [18] and systemic
inflammatory [17] influence upon vascular endothelium,
potentially initiating or propagating the development of
atherosclerosis. This theory is supported by a study showing a correlation between CT-based ITFV measures and
serum levels of hsCRP [6], a validated systemic inflammatory marker of CAD risk [17,19,20].
Evidence for an increased prevalence of atherosclerotic
disease in patients with higher intra-thoracic fat volumes
has been reported in studies employing thoracic CT imaging [6,7]. These studies, similarly executed from retrospective cohort data, evaluated patients receiving clinical
cardiac CT and showed an association between ITFV
and coronary artery calcification. The first study, reported
by Dey et al. [6], identified that ITFV was significantly
higher in those with versus without MetS (p < 0.0001) and
showed a strong correlation with the coronary calcium
score (r = 0.79, p <0.0001). In a second study, by Yun et al.
[7], patients within the highest quartile of ITFV had a
four-fold higher prevalence of coronary artery calcification. In combination, these studies provided compelling
evidence that thoracic visceral adiposity is associated with
a higher prevalence of coronary atherosclerosis. Interestingly, a recent study by Brinkley, et al. [21] failed to show
pericardial fat volume, a component of ITFV, to be independently associated with hyperemic myocardial blood
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Figure 5 Results of Intra-observer and Inter-observer reproducibility testing for ITFV measurement from HASTE CMR, shown using
both linear regression analysis (upper) and Bland-Altman analysis (lower).

flow or myocardial perfusion reserve. However, this study
was performed in asymptomatic low risk individuals with
a low prevalence of diabetes.
The validation of thoracic fat volume measurements
for the prediction of CAD-related events in patients with
MetS is clinically attractive. Incremental discrimination
of high-risk individuals more likely to benefit from early
and aggressive pharmacologic intervention or ischemia
surveillance is of importance. Farouzandeh et al. recently
showed ITFV by cardiac CT to be independently associated with major adverse cardiovascular events among a
broad population of patients referred for acute chest
pain [8]. Our study provides evidence that ITFV is elevated in patients with MetS, but incrementally elevated
among those with MetS experiencing ischemic myocardial events. This suggests that this imaging biomarker
may of value for the discrimination and monitoring of
cardiovascular risk among patients with MetS. Accordingly, we feel there is strong impetus and justification
for related prognostic studies to be engaged in this patient population.
While echocardiography is highly accessible, and provides reproducible linear measures of pericardial fat thickness [20], these results appear to be less well correlated
with true volumetric measures of visceral adiposity or systemic metabolic abnormalities [22]. While both routine
CMR and CT protocols offer tomographic imaging that
can provide appropriate datasets for intra-thoracic fat
quantification, the lack of ionizing radiation with CMR
techniques offers a particular advantage. Routine SSFPbased cine imaging can provide for simple linear measurements of pericardial fat thickness, and has been
shown to be predictive of future atrial fibrillation [23].
However, such measurements are inherently dependent
upon the architecture of pericardial fat relative to prescribed

imaging planes, and may not accurately represent total
visceral fat. Fat-water separation techniques are of increasing importance for accurate fat quantification and
offer a potentially robust approach to volumetric assessments [24]. While currently still in a development phase,
these techniques are of particular interest for future clinical research. The advantage of our currently described
technique is that it is simple, immediately available, and
reliably performed during shallow, free breathing in under
one minute. Further, the images can be prescribed as
standard “localizers” for the initiation of routine cardiac
imaging protocols.
Study limitations

As a retrospective cohort study, performed within a singlecenter CMR clinical registry, these findings require confirmation within a larger multi-center setting.
The CMR protocol incorporated the use of gadoliniumbased contrast for the performance of LGE imaging.
Accordingly, patients with significant renal insufficiency
(GFR <30 ml/min/1.73 m2) were not included due to FDA
warnings of its use in such patients. Extrapolation of study
findings to such patients may not be appropriate.
The available healthy control population (MetS-/MI-)
from the employed registry was modest in size due to
the registry’s mandate to recruit patients with known
or suspected cardiovascular disease. Accordingly, case
matching of age and sex variables was not feasible and
potentially introduces bias for comparisons among this
group. However, significant differences in ITFV were
identified between disease cohorts (ie: MetS+/MI- versus
MetS+/MI+), supporting that ITFV is indeed associated
with the occurrence of MI among those with MetS.
Finally, the small number of female patients, most notably in the MetS+/MI- and MetS-/MI- groups, presents
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a limitation for generalizability of our current findings.
Therefore, we recommend validation of our findings
within a larger population with more balanced gender
representation.

Conclusions
Intra-thoracic visceral fat, as represented by an indexed
ITFV, is elevated among patients with MetS, is incrementally
elevated among those suffering from myocardial infarction
and appears to be an independent predictor of total infarct
burden. These findings justify the performance of larger,
prospective cohort studies evaluating the utility of ITFV
measurement for the prediction of future cardiovascular
events among patients with MetS.
Consent

Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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